Prostate Cancer Risk Assessment Using Genetic Markers in General Practice
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- University of Aarhus
- Enrollment
- 5000
- Locations
- 1
- Primary Endpoint
- Number of low risk patients who get a PSA test
- Status
- Active, Not Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
The preferred method for early detection of prostate cancer (PCa) in older men with family history is the Prostate Specific Antigen test (PSA test), although the method is imprecise. It produces a high number of false-positive results and increases the risk of over-diagnosis and over-treatment. Yet, an increasing number of men get the PSA test as part of unsystematic screening. Genetic risk assessment may be a better way to identify men with low risk of PCa. The main study hypothesis is that genetic information about low risk of PCa can reduce the number of patients who get a PSA test as part of unsystematic screening.
Investigators
Eligibility Criteria
Inclusion Criteria
- •patients who receive a PSA test
Exclusion Criteria
- •age over 80 years
- •elevated PSA-level (\> 4,0 ng/ml) concurrently or within previous 2 years
- •prostate or bladder disease
- •prostate cancer
- •non-Caucasians
- •do not speak and understand Danish
Outcomes
Primary Outcomes
Number of low risk patients who get a PSA test
Time Frame: 1 year, 2 years
The primary objective of this study is to evaluate the impact on use of PSA tests of introducing genetic PCa risk assessment in general practice.